Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6541369 | 0.79 | OPRM1 (0.32) | CYP2D6OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL4443246 | 0.70 | CYP2D6 (0.37) | CYP2D6MC4R | |
| SCHEMBL7007764 | 0.69 | SLC6A2 (0.37) | — | |
| Hydrochloric Acid SCHEMBL6540298 | 0.68 | SLC6A2 (0.36) | — | |
| Hydrochloric Acid SCHEMBL6336901 | 0.68 | SLC6A2 (0.36) | — | |
| Hydrochloric Acid SCHEMBL6541046 | 0.68 | SLC6A2 (0.36) | — | |
| SCHEMBL6541207 | 0.66 | DAO (0.36) | CYP2D6OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL27991724 | 0.66 | POLB (0.50) | NPSR1GPR55POLBHTT | |
| SCHEMBL6540248 | 0.66 | DAO (0.36) | CYP2D6 | |
| SCHEMBL1502251 | 0.65 | SLC6A4 (0.50) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787543-B2 | PREPARATION OF TACHYKININ ANTAGONISTS; SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030176430-A1 | Benzhydryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176430-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | NPSR1 25/4885GPR55 459/4885CYP2D6 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.